Renalytix Announces Financing with Expected Size of up to $4 Million
Both tranches are priced at $0.75 per NASDAQ ADS ($0.375 per Ordinary Share).
- Both tranches are priced at $0.75 per NASDAQ ADS ($0.375 per Ordinary Share).
- The aggregate total amount for both tranches, if the option is fully exercised, is expected to be up to $4 million in total financing.
- The net proceeds of the Fundraise will be used to support commercial sales activity as the Company continues its Formal Sale Process, as previously announced.
- The completion of the sale and purchase of the Initial Tranche Shares is expected take place no later than 11 April 2024, subject to customary closing conditions.